These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33176391)

  • 21. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
    Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
    BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population.
    Itoga NK; Rothenberg KA; Suarez P; Ho TV; Mell MW; Xu B; Curtin CM; Dalman RL
    J Vasc Surg; 2019 Mar; 69(3):710-716.e3. PubMed ID: 30197158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006.
    Foster PD; Mamdani MM; Juurlink DN; Shah BR; Paterson JM; Gomes T
    Diabet Med; 2013 Oct; 30(10):1209-13. PubMed ID: 23586333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
    Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
    Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Description of a French Population of Diabetics Treated Followed up by General Practitioners.
    Fruchart M; Lamer A; Lemaitre M; Beuscart JB; Calafiore M; Quindroit P
    Stud Health Technol Inform; 2023 May; 302():856-860. PubMed ID: 37203517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults.
    Raghavan S; Warsavage T; Liu WG; Raffle K; Josey K; Saxon DR; Phillips LS; Caplan L; Reusch JEB
    Diabetes Care; 2022 Jun; 45(6):1335-1345. PubMed ID: 35344584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men.
    Rosell-Díaz M; Petit-Gay A; Molas-Prat C; Gallardo-Nuell L; Ramió-Torrentà L; Garre-Olmo J; Pérez-Brocal V; Moya A; Jové M; Pamplona R; Puig J; Ramos R; Bäckhed F; Mayneris-Perxachs J; Fernández-Real JM
    Metabolism; 2024 Aug; 157():155941. PubMed ID: 38871078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.
    Xu Y; Pilla SJ; Alexander GC; Murimi IB
    PLoS One; 2019; 14(2):e0211820. PubMed ID: 30759121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus.
    Wu CT; Tsai YT; Jung HK; Fu SL; Hsiung CA; Liu HY; Lai JN
    J Clin Pharmacol; 2022 Feb; 62(2):276-284. PubMed ID: 34510471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis.
    Filion KB; Joseph L; Boivin JF; Suissa S; Brophy JM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):973-6. PubMed ID: 19621344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antidiabetic drugs prescription patterns among a group of patients in Colombia].
    Machado Alba JE; Moncada Escobar JC; Mesa Escobar G
    Rev Panam Salud Publica; 2007 Aug; 22(2):124-31. PubMed ID: 17976279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
    Johnson JA; Majumdar SR; Simpson SH; Toth EL
    Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to metformin monotherapy in people with type 2 diabetes mellitus in New Zealand.
    Horsburgh S; Barson D; Zeng J; Sharples K; Parkin L
    Diabetes Res Clin Pract; 2019 Dec; 158():107902. PubMed ID: 31672501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression through diabetes therapies among new elderly users of metformin: a population-based study.
    Gomes T; Juurlink DN; Shah BR; Hellings CR; Paterson JM; Mamdani MM
    Diabet Med; 2013 Feb; 30(2):e51-5. PubMed ID: 23075391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.